NUTRITIONAL CHROMIUM COMPOSITIONS AND METHODS OF USE

Abstract

The chromium compositions and methods of use for patients with glucose intolerance comprising a chromium complex in combination with at least one amino acid, niacinamide, and salicylic acid.

Claims

1. A pharmaceutical composition of chromium supplement comprising a chromium complex in combination with pyridine-3-carboxamide, and 2-amino-5-(diaminomethylidene amino) pentanoic acid.

2. The pharmaceutical composition of claim 1 further comprises 2-hydroxybenzoic acid

3. The pharmaceutical composition of claim 1 further comprises a pharmaceutically acceptable carrier, adjuvant, excipient or diluent.

4. The pharmaceutical composition of claim 3, wherein said pharmaceutically acceptable carrier is selected from the group consisting a pill, capsule, lozenge, caplet, syrup, emulsion, suspensional liquid, powder, spray, cream or lotion.

5. The pharmaceutical composition of claim 1, wherein said chromium complex is selected from the group consisting of chromium picolinate, chromium nicotinate, chromium glycinate, or other chromium comprising chromium content of between about 100 to 1,500 micrograms.

6. The pharmaceutical composition of claim 1 is in unit dosage form.

7. A method for increasing absorption of chromium supplement in a human subject, said method comprises administering to said human subject an effective amount of the pharmaceutical composition of claim 1.

8. The method of claim 7, wherein the pharmaceutical composition is administered in combination with a pharmaceutically acceptable carrier.

9. The method of claim 8, wherein the pharmaceutically acceptable carrier is further selected from the group consisting a pill, capsule, lozenge, caplet, syrup, emulsion, suspensional liquid, powder, spray, cream or lotion.

10. The method of claim 7, wherein the pharmaceutical composition is administered orally, nasally, sublingually, intramuscularly, subcultaneously, and transdermally.

Description

BRIEF DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0027] In one embodiment, the chromic complex, pyridine-3-carboxamide, and 2-amino-5-(diaminomethylidene amino) pentanoic acid may be incorporated into a tablet, aqueous or oil suspension, dispersible powder or granule, emulsion, hard or soft capsule, syrup or elixir.

[0028] In other preferred embodiment, the amino acid may be selected from cysteine, glutamine, glycine, proline, and tyrosine.

[0029] In other preferred embodiment, the components of the composition may also be administered separately. Compositions may be prepared in according any method known in the art for the manufacture of pharmaceutically acceptable compositions and such compositions may contain one or more of the following agents: sweeteners, flavoring agents, coloring agents and preservatives. Tablets containing the active ingredients in admixture with non-toxic pharmaceutically acceptable excipients suitable for tablet manufacture are acceptable.

[0030] In other preferred embodiment, dispersible powders and granules of the invention suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent, and one or more preservatives. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.

[0031] In other preferred embodiment, the dosage range of chromium administered to an individual in the form of chromium/niconitic acid/arginine/salicylic acid, or chromium/niacinamide/arginine provides between about 100 and 1,000 micrograms per day of chromium; preferably between about 200 and 1,000 micrograms per day; more preferably, between about 100 and 500 micrograms per day.

[0032] In other preferred embodiment, the ratio of chromium to niacinamide/arginine ranges from about 10:1 to about 1:10 (w/w), more preferably from about 5:1 to about 1:5 (w/w).

[0033] It will be appreciated that although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

[0034] The compositions are administered in any suitable manner, often with pharmaceutically acceptable carriers. Suitable methods of administering compositions in the context of the present invention to a subject are available, and, although more than one route can be used to administer a particular composition, a particular route can often provide a more immediate and more effective reaction than another route.

[0035] The compositions are administered in any suitable manner, often with pharmaceutically acceptable carriers. Suitable methods of administering compositions in the context of the present invention to a subject are available, and, although more than one route can be used to administer a particular composition, a particular route can often provide a more immediate and more effective reaction than another route.

[0036] The present invention is further illustrated by the following examples, which should not be construed as limiting in any way. The contents of all cited references throughout this application are hereby expressly incorporated by reference. The practice of the present invention will employ, unless otherwise indicated, conventional techniques of pharmacology and pharmaceutics, which are within the skill of the art.

[0037] Therefore, those skilled in the art will appreciate that the conceptions and specific embodiments disclosed in this description may be readily utilized as a basis for modifying or designing other embodiments for carrying out the same purposes of the present invention. Those skilled in the art will also appreciate that such equivalent embodiments do not depart from the spirit and scope of the invention as set forth in the appended claims.

[0038] Throughout this application various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to describe more fully the state of the art to which this invention pertains.

[0039] As various modifications could be made to the exemplary embodiments, as described above with reference to the corresponding illustrations, without departing from the scope of the invention, it is intended that all matter contained in the foregoing description and shown in the accompanying drawings shall be interpreted as illustrative rather than limiting. Thus, the breadth and scope of the present invention should not be limited by any of the above described exemplary embodiments, but should be defined only in accordance with the following claims appended hereto and their equivalents.